TCGA-35-4122-01A-01R-1107-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.540
- INFLAMMATORY_RESPONSE+0.470
- INTERFERON_GAMMA_RESPONSE+0.470
- INTERFERON_ALPHA_RESPONSE+0.460
- OXIDATIVE_PHOSPHORYLATION+0.460
- IL6_JAK_STAT3_SIGNALING+0.450
- COMPLEMENT+0.400
- PANCREAS_BETA_CELLS+0.380
- TNFA_SIGNALING_VIA_NFKB+0.370
- KRAS_SIGNALING_UP+0.360
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.560
- MITOTIC_SPINDLE-0.490
- HEDGEHOG_SIGNALING-0.370
- G2M_CHECKPOINT-0.250
- UV_RESPONSE_DN-0.250
- ESTROGEN_RESPONSE_EARLY-0.140
- APICAL_SURFACE-0.130
- NOTCH_SIGNALING-0.080
- TGF_BETA_SIGNALING-0.080
- ANDROGEN_RESPONSE-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.934 |
| 2 | TCGA-50-5066-01A-01R-1628-07 | — | cohortA1 | 0.919 |
| 3 | TCGA-D8-A1Y2-01A-11R-A157-07 | — | C | 0.909 |
| 4 | TCGA-35-4123-01A-01R-1107-07 | — | cohortA1 | 0.908 |
| 5 | AUR-AFUI-TTM1-A-1-0-R-A743-41 | — | C | 0.907 |
| 6 | TCGA-38-4632-01A-01R-1755-07 | — | cohortA1 | 0.899 |
| 7 | TCGA-64-1676-01A-01R-0946-07 | — | cohortA1 | 0.899 |
| 8 | TCGA-33-4589-01A-01R-1443-07 | — | cohortSQ1 | 0.873 |
| 9 | TCGA-37-3783-01A-01R-1201-07 | — | cohortSQ1 | 0.871 |
| 10 | AUR-AFR2-TTP1-A-1-1-R-A742-41 | — | C | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.540 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |